Cargando…
Stakeholder Views on the Idea of Medicines Reuse in the UK
People’s views about medicines reuse are being examined in a handful of qualitative studies and this commentary adds to that work by drawing on our own discussions with groups of stakeholders in the UK in the past two years. The reuse of medicines within the community pharmacy setting is not permitt...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167662/ https://www.ncbi.nlm.nih.gov/pubmed/33923745 http://dx.doi.org/10.3390/pharmacy9020085 |
_version_ | 1783701741071499264 |
---|---|
author | Donyai, Parastou McCrindle, Rachel Hui, Terence K. L. Sherratt, R. Simon |
author_facet | Donyai, Parastou McCrindle, Rachel Hui, Terence K. L. Sherratt, R. Simon |
author_sort | Donyai, Parastou |
collection | PubMed |
description | People’s views about medicines reuse are being examined in a handful of qualitative studies and this commentary adds to that work by drawing on our own discussions with groups of stakeholders in the UK in the past two years. The reuse of medicines within the community pharmacy setting is not permitted in the UK but our multidisciplinary team anticipates that this position will change in the coming years as medication shortages and worries about environmental waste and financial losses from the destruction of unused medicines are brought to the fore. Indeed, for many stakeholders, the issue of waste is a strong feature of conversations about medicines reuse. In addition to this, stakeholders identify the numerous barriers to medicines reuse in the UK. This includes the current uncertainty about the quality of unused medicines returned to pharmacies, which could otherwise be reused. However, stakeholders have also been very willing to propose solutions to a range of existing barriers. Our commentary draws on stakeholder meetings to elaborate the range of views about medicines reuse within a UK context. The challenge is to move forward from these views to advance the technologies that will facilitate medicines reuse practically as well as legally. |
format | Online Article Text |
id | pubmed-8167662 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81676622021-06-02 Stakeholder Views on the Idea of Medicines Reuse in the UK Donyai, Parastou McCrindle, Rachel Hui, Terence K. L. Sherratt, R. Simon Pharmacy (Basel) Commentary People’s views about medicines reuse are being examined in a handful of qualitative studies and this commentary adds to that work by drawing on our own discussions with groups of stakeholders in the UK in the past two years. The reuse of medicines within the community pharmacy setting is not permitted in the UK but our multidisciplinary team anticipates that this position will change in the coming years as medication shortages and worries about environmental waste and financial losses from the destruction of unused medicines are brought to the fore. Indeed, for many stakeholders, the issue of waste is a strong feature of conversations about medicines reuse. In addition to this, stakeholders identify the numerous barriers to medicines reuse in the UK. This includes the current uncertainty about the quality of unused medicines returned to pharmacies, which could otherwise be reused. However, stakeholders have also been very willing to propose solutions to a range of existing barriers. Our commentary draws on stakeholder meetings to elaborate the range of views about medicines reuse within a UK context. The challenge is to move forward from these views to advance the technologies that will facilitate medicines reuse practically as well as legally. MDPI 2021-04-16 /pmc/articles/PMC8167662/ /pubmed/33923745 http://dx.doi.org/10.3390/pharmacy9020085 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Commentary Donyai, Parastou McCrindle, Rachel Hui, Terence K. L. Sherratt, R. Simon Stakeholder Views on the Idea of Medicines Reuse in the UK |
title | Stakeholder Views on the Idea of Medicines Reuse in the UK |
title_full | Stakeholder Views on the Idea of Medicines Reuse in the UK |
title_fullStr | Stakeholder Views on the Idea of Medicines Reuse in the UK |
title_full_unstemmed | Stakeholder Views on the Idea of Medicines Reuse in the UK |
title_short | Stakeholder Views on the Idea of Medicines Reuse in the UK |
title_sort | stakeholder views on the idea of medicines reuse in the uk |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167662/ https://www.ncbi.nlm.nih.gov/pubmed/33923745 http://dx.doi.org/10.3390/pharmacy9020085 |
work_keys_str_mv | AT donyaiparastou stakeholderviewsontheideaofmedicinesreuseintheuk AT mccrindlerachel stakeholderviewsontheideaofmedicinesreuseintheuk AT huiterencekl stakeholderviewsontheideaofmedicinesreuseintheuk AT sherrattrsimon stakeholderviewsontheideaofmedicinesreuseintheuk |